NeuroMab™ Anti-S100B BBB Shuttle Antibody,Clone NR2351P

Fig.1 S100B«TLR4 is present in sporadic and familial human AD specimens.

Representative micrographs of sporadic (olfactory cortex) and familial (cingulate gyrus) AD human specimens processed using S100B (BL356) and counterstained with hematoxylin to visualize nuclei (blue; dashed arrows). Bars = 50 μm.

Fig.2 Anti-SlOOB (BL356) antibody crosses the blood brain barrier and neutralizes S100B.

The fig contains representative micrographs of sections from S100B+/+ or S100B_/" mice stained with the anti-SlOOB (BL356) antibody (Bethyl Laboratories) (red) and counterstained with DAPI (blue) to visualize nuclei. Bars = 20 μιη.

Fig.3 Neutralization of extracellular S 100B blocks TLR4/NF-KB signaling.

Representative micrographs of parasagittal cortical sections from 7.5 month old PSAPP mice treated with an anti-SlOOB antibody (BL356) or isotype control -IgG/placebo and processed using S100B + TLR4 primary antibodies (brown; solid arrows) and counterstained with hematoxylin to visualize nuclei (blue; dashed arrows).

Fig.4 Dose-response curves for engineered antibodies.

A direct ELISA and serial dilutions ranging from 0.0025 to 83 micrograms were used to generate dose-response curves for engineered antibodies.

Fig.5 muBL356(lC8) Detection.

Indirect ELISAs were used to detect muBL356(lC8) in PBS and serum. The data are expressed as the mean percent binding ± the SEM (n=3). The shift in the dose response curve indicates that quantitative data can be obtained if control and experimental samples contain equivalent concentrations of serum.